Biotech Values

[DewDiligence]

FDA approves EXAS’ Cologuard stool-based test for CRC:

http://www.bloomberg.com/news/2014-08-11/exact-sciences-wins-u-s-approval-for-colon-cancer-test.html

The test is also the first to go through a parallel review by the FDA and the Centers for Medicare and Medicaid Services, which makes determinations on whether to cover the cost of products for the U.S. health program for the elderly and disabled. CMS plans to cover Cologuard once every three years for Medicare beneficiaries who are 50 to 85, don’t show symptoms of colorectal cancer and who carry an average risk of developing the cancer.

The three-year testing interval for reimbursement was as expected, although self-pay patients could conceivably test as often as, say, once per year. EXAS has not yet announced the price of the test.